Understanding Malignancy Risks With the Use of CAR T-cell Therapies
Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.
CAR T-Cell Therapy as a Second-Line Treatment for LBCL
Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.
Sequencing With CAR T-Cell Therapy for LBCL
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.
The Expanding Utility of CAR T-Cell Therapy in LBCL
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss the trajectory and role of of CAR T-cell therapy within the treatment spectrum for LBCL.
Monitoring and Support for Patients Receiving CAR T-Cell Therapy
Experts discuss providing supportive care to patients receiving CAR T-cell therapy.
Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma
Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies
Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.
